Download MendeleyA matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention.
Kwon, Y.D., Asokan, M., Gorman, J., Zhang, B., Liu, Q., Louder, M.K., Lin, B.C., McKee, K., Pegu, A., Verardi, R., Yang, E.S., Program, V.P., Carlton, K., Doria-Rose, N.A., Lusso, P., Mascola, J.R., Kwong, P.D.(null) MAbs 13: 1946918-1946918
- PubMed: 34328065
- DOI: https://doi.org/10.1080/19420862.2021.1946918
- Primary Citation of Related Structures:
6VI0 - PubMed Abstract:
Passive transfer of broadly neutralizing antibodies is showing promise in the treatment and prevention of HIV-1. One class of antibodies, the VRC01 class, appears especially promising. To improve VRC01-class antibodies, we combined structure-based design with a matrix-based approach to generate VRC01-class variants that filled an interfacial cavity, used diverse third-complementarity-determining regions, reduced potential steric clashes, or exploited extended contacts to a neighboring protomer within the envelope trimer. On a 208-strain panel, variant VRC01.23LS neutralized 90% of the panel at a geometric mean IC 80 less than 1 μg/ml, and in transgenic mice with human neonatal-Fc receptor, the serum half-life of VRC01.23LS was indistinguishable from that of the parent VRC01LS, which has a half-life of 71 d in humans. A cryo-electron microscopy structure of VRC01.23 Fab in complex with BG505 DS-SOSIP.664 Env trimer determined at 3.4-Å resolution confirmed the structural basis for its ~10-fold improved potency relative to VRC01. Another variant, VRC07-523-F54-LS.v3, neutralized 95% of the 208-isolated panel at a geometric mean IC 80 of less than 1 μg/ml, with a half-life comparable to that of the parental VRC07-523LS. Our matrix-based structural approach thus enables the engineering of VRC01 variants for HIV-1 therapy and prevention with improved potency, breadth, and pharmacokinetics.
Organizational Affiliation:
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
